Although a comparable pattern was observed in patients with HER2-amplified breast cancer, the difference was not statistically significant (P > 0.05), possibly because of the small number of participants in this specific patient cohort (Supplementary Figure 2B). This evidence concerns the gene ERBB2 and breast cancer.